Antibiotics: How to fix a broken market
Antibiotics stopped providing big gains for pharmaceutical companies decades ago, but as bacteria become more resistant to drugs, the world needs new classes of antibiotics to be discovered if we want to prevent the next global health crisis.
Dr Tina Joshi, Associate Professor of Molecular Microbiology at the University of Plymouth explains that it’s more likely antimicrobial resistance will kill large numbers of human beings before climate change does. Kasim Kutay, CEO of the investment fund Novo Holdings tells us that for big pharma companies, antibiotics are seen as a contribution to society rather than an investment that can provide a profit.
How can firms be convinced to invest in an unprofitable product? We hear how Netflix might provide a good model and we explore research in Phages - a bacteria specialised in eating other bacteria. Phages are being championed by some as a potential substitute for antibiotics. One patient in Minnesota tells us Phages saved his life.
Presenter / producer: Stefania Gozzer Image: Dr Tina Joshi; Credit: Lloyd Russell
You May Also Like

The Lucy Ann Lance Show
Cumulus Media Detroit
Company Interviews
Crux Investor

The KE Report
KE Report

CNBC Business News Update
CNBC

Børsmorgen & Økonominyhetene
Finansavisen

Onramp Bitcoin Media
Onramp Bitcoin

Flipping Mastery Podcast
Jerry Norton

Inversión Dividendos
Carlos García

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT
WELT

Mining Stock Daily
Trevor Hall
Community discussion